Seems not many people understand fully the actual businesses that AA involved with...not just carrying passengers through their fleet of airplanes

WOW...AI and RPA for AA

SEPANG, 13 AUGUST 2020 – AirAsia Group is accelerating its ongoing digital transformation journey further by implementing robotic process automation (RPA) in collaboration with Silicon Valley and India-based enterprise automation platform JIFFY.ai.


Chief Transformation Officer Azli Mohamed said the implementation of RPA followed a review of AirAsia’s internal processes and workflows, which showed that business process automation can be done easily with the right tools in place.


“At AirAsia, we continuously seek to push the boundaries of innovation. RPA will allow our workforce to automate mundane and repetitive tasks, which will free up valuable time to focus on other tasks that require thinking and experience-based judgment.


“RPA will enable us to increase productivity, reduce errors and redeploy resources to higher-value functions. All these benefits will ultimately translate into sizable cost savings and top-line revenue growth.”


AirAsia has appointed India- and US-based JIFFY.ai to initiate its RPA adoption, which began in May 2020. The implementation leverages JIFFY.ai’s artificial intelligence (AI)-enabled automation platform, which brings intelligent automation, intelligent document processing and analytics together in a single solution.


“We are delighted to have been chosen as the partner for AirAsia to help them on their digital transformation journey,” said Babu Sivadasan, Co-founder and Chief Executive Officer, JIFFY.ai. “The JIFFY.ai AUTOMATE platform is expandable and extensible and will give them the intelligent automation power they need to streamline and improve complex business processes while supporting innovation to help the business grow.”

OURSHOP is an e-commerce marketplace, owned by AirAsia to spur the growth of local products by developing traditional small and medium businesses to be e-commerce ready. To top it all off, shoppers can also earn BIG Points with every successful purchase made, and even use BIG Points to pay for their shopping.

Kuala Lumpur, 13 August 2020 - Following on from the success of the Save Our Shops (S.O.S) campaign in April 2020, AirAsia’s logistics arm Teleport is gearing up to launch another campaign called “Shop Sama Kamek”. This campaign is held in conjunction with the Government’ Short-Term Economic Recovery Plan (PENJANA) Micro and SMEs (MSMEs) E-commerce Campaign that was rolled out in June by the Malaysia Digital Economy Corporation (MDEC). The “Shop Sama Kamek” campaign will be launched specifically to support more East Malaysia merchants to sell food items online on OURSHOP, AirAsia’s e-commerce platform in September.


With the launch of this “Shop Sama Kamek” campaign, OURSHOP will recruit a total of 300 merchants from small and medium enterprises in East Malaysia ranging from food categories of fresh, frozen and packaged food.


“In order to fulfill our campaign needs and revive the local economy, we have received approval by the Government for a grant to initiate cross-border delivery, marketing efforts and training for merchants. This will allow us to provide the necessary resources and needs to support merchants in East Malaysia to be E-commerce ready”, said Pete Chareonwongsak, CEO of Teleport.

AirAsia businesses including e-commerce marketplace called OURSHOP....big money coming !!

You thought Malaysian investors so stupid ?

A bunch of kanasai assumptions

Might reach RM118 next year and RM288 in 2022 if another pandemic happen in the near future....if if if...

Vaccine coming very soon.... its no joke

With one billion financial assistance from bank and financial institutions that already approved and more assistance coming soon plus AA own efforts in reducing their debts, AA will certainly be able to continue to serve ordinary ppl like us for many years to come.

Smart investors looking ahead and they know AA is a very good company and if not because of covid-19, AA share should easily worth 2.00 today. Don't forget AA already won many awards for many years as the best low cost airline in Asia.

Buyers not stupid la... they also know what you know, ppl already expected the coming qr based on earning reports by SIA, CP and other major airline companies.

Aiyoyo...profit already in the bank account since early last week, still worry about qr ?

This blogger still living in the past

Kanasai report from rubbish research

Only their sharks are playing

Heart attack looking at gold price down more than five percent yesterday...make sure you're healthy enough to spend your wealth. Look at the price movement of the stock yesterday confirmed it's not because of huge earning but big shark is controlling the price now.

Today 8 cents next week 10 cents...1 cent maybe 100 years later

So pity those still waiting at 20 cents...another 100 years of waiting. Profit already in the bank. Cheers !

TF and Kamaruddin going to push up to 1.00

Accumulation done ? Good ! Small fish entering soon.

No wonder Topglov dropped so much...top loser ! Vaccine coming soon...runnnnn !

You can't control human greediness....see who would receive the final baton. Definitely its not me !

Vaccine coming soon...still doing the unnecessary calculation. Just make sure you don't earn less or loss money.

Big shark already accumulate WTK yesterday, that's why the news is out...as usual. The greedy small fish still join the big shark knowingly they going to be the baits but human greediness will not deter them from dreaming to become richer.

Today 80 cents within reach

Congrats to those who managed to sell above 5.00. Never too greedy in share trading. You'll never know when the big correction is coming. With more vaccine news coming out means glove stocks going to continue to correct itself. Happy days over for glove stocks ?

Congrats to those who managed to sell above 5.00. Never too greedy in share trading. You'll never know when the big correction is coming. With more vaccine news coming out means glove stocks going to continue to correct itself. Happy days over for glove stocks ?

Pity those kiasi small fish still waiting to buy AAX at 1 cent or even 3 cents...hahahaha.

TF and Kamaruddin know that now is the best time to add more AA shares. Tomorrow AA going to challenge 80 cents.


Pursuant to Paragraph 14.08(b) of the Main Market Listing Requirements of Bursa Malaysia Securities Berhad, AirAsia Group Berhad ("AirAsia" or the "Company") wishes to announce that Tan Sri Anthony Francis Fernandes, a Non-Independent Executive Director and Chief Executive Officer of AirAsia, intends to deal in the securities of AirAsia during the closed period prior to the release of the Second Quarter results for the year 2020.

So many idiotic thinking about AA...look at what happened to glove stocks today and look at Genting Malaysia and Genting share prices today definitely a direct signal that covid-19 could be defeated soon with so many vaccines going to come out soon, starting with vaccine from Russia. Cheers !

Kiasi and kiasu can't get AA at 30 cents....wait until next pandemic 100 years later maybe can get at 30 cents...hahahaha

From Russia with love

Russia says medics to get anti-COVID shots in two weeks, rejects safety concerns
WORLD
Wednesday, 12 Aug 2020 4:05 PM MYT

MOSCOW (Reuters) - Russia said on Wednesday the first batch of its Covid-19 vaccine would be
ready tor some medicS within two weeks and rejected as "groundless" safety concerns aired by
some experts over Moscow's rapid approvalof the drug.

President Vladimir Putin said on Tuesday that Russia had become the first country to grant
regulatory approval to a COVID-19 vaccine, after less than two months of human testing.

Today's buyers still hungry for more AA shares as they know the price of AA still very cheap. Most investors already discounted the weak second qr ahead. Investors now looking forward to better earnings from AA especially for the financial results in 2021.

Those kiasi and kiasu small fish must be kicking themselves now for not trusting TF and AA.

TP 80 cents by Friday... many many good news for AA will help AA challenge 1.00 by end of August.

Early last week Tomei only traded around 50 cents. Back to square one this week ??

Another limit down today very likely as gold price slump another 1.5% as of now !! No hope for rebound.

Limit down today very likely as gold price slump another 1.5% as of now !! No hope for rebound.

Major shareholders very smart... millions of PohKong shares sold off last week during the limit up period. Who is the lucky one holding their share now ?? Heading south today... definitely as gold price slumped 4.3% as now in world market !!

Vaccine coming very soon...no joke !!

JAKARTA, Aug 11 — China's Sinovac Biotech Ltd launched today a late-stage human trial involving as many as 1,620 patients in Indonesia for a Covid-19 vaccine candidate that it is developing with Indonesian state-owned peer Bio Farma.

The candidate, known as CoronaVac and previously PiCoVacc, is among few potential vaccines that have entered late-stage trials for a large-scale study to gather proof of efficacy for regulatory approval.

CoronaVac is already undergoing a late-stage trial in Brazil slated for as many as 9,000 people.

Its Indonesia trial comes as South-east Asia's most populous country grapples with spiking infection numbers, with over 127,000 cases recorded as of today. The trial has so far recruited 1,215 people and will last six months.

A ceremony for the launch today in Bandung, West Java, was attended by Indonesia's President Joko Widodo.

“The threat of Covid-19 will not subside until a vaccine is given to all the people,” Widodo said.

Sinovac expects to also test the vaccine candidate in Bangladesh.

Separately, Sinovac late yesterday released details from a mid-stage, or Phase 2, study in which it said the vaccine candidate appeared to be safe and induced detectable antibody-based immune responses in subjects.

In the Phase 2 clinical trial involving 600 participants in China, the candidate did not cause any serious side effect and the rate of fever was relatively low compared with other Covid-19 candidates, the paper showed ahead of peer review.

Sinovac has to test its vaccine abroad because China is no longer a satisfactory site for late-stage trials due to the low number of new infection cases.

https://www.theedgemarkets.com/article/russia-approves-first-covid19-vaccine-putin-says

Party for glove stocks going to stop soon ! BEWARE !!

https://www.theedgemarkets.com/article/russia-approves-first-covid19-vaccine-putin-says

Vaccine coming very soon...no joke !! All glove stocks going to holland soon.

JAKARTA, Aug 11 — China's Sinovac Biotech Ltd launched today a late-stage human trial involving as many as 1,620 patients in Indonesia for a Covid-19 vaccine candidate that it is developing with Indonesian state-owned peer Bio Farma.

The candidate, known as CoronaVac and previously PiCoVacc, is among few potential vaccines that have entered late-stage trials for a large-scale study to gather proof of efficacy for regulatory approval.

CoronaVac is already undergoing a late-stage trial in Brazil slated for as many as 9,000 people.

Its Indonesia trial comes as South-east Asia's most populous country grapples with spiking infection numbers, with over 127,000 cases recorded as of today. The trial has so far recruited 1,215 people and will last six months.

A ceremony for the launch today in Bandung, West Java, was attended by Indonesia's President Joko Widodo.

“The threat of Covid-19 will not subside until a vaccine is given to all the people,” Widodo said.

Sinovac expects to also test the vaccine candidate in Bangladesh.

Separately, Sinovac late yesterday released details from a mid-stage, or Phase 2, study in which it said the vaccine candidate appeared to be safe and induced detectable antibody-based immune responses in subjects.

In the Phase 2 clinical trial involving 600 participants in China, the candidate did not cause any serious side effect and the rate of fever was relatively low compared with other Covid-19 candidates, the paper showed ahead of peer review.

Sinovac has to test its vaccine abroad because China is no longer a satisfactory site for late-stage trials due to the low number of new infection cases.

https://www.theedgemarkets.com/article/russia-approves-first-covid19-vaccine-putin-says

Vaccine coming very soon...no joke !! All glove stocks going to holland soon.

JAKARTA, Aug 11 — China's Sinovac Biotech Ltd launched today a late-stage human trial involving as many as 1,620 patients in Indonesia for a Covid-19 vaccine candidate that it is developing with Indonesian state-owned peer Bio Farma.

The candidate, known as CoronaVac and previously PiCoVacc, is among few potential vaccines that have entered late-stage trials for a large-scale study to gather proof of efficacy for regulatory approval.

CoronaVac is already undergoing a late-stage trial in Brazil slated for as many as 9,000 people.

Its Indonesia trial comes as South-east Asia's most populous country grapples with spiking infection numbers, with over 127,000 cases recorded as of today. The trial has so far recruited 1,215 people and will last six months.

A ceremony for the launch today in Bandung, West Java, was attended by Indonesia's President Joko Widodo.

“The threat of Covid-19 will not subside until a vaccine is given to all the people,” Widodo said.

Sinovac expects to also test the vaccine candidate in Bangladesh.

Separately, Sinovac late yesterday released details from a mid-stage, or Phase 2, study in which it said the vaccine candidate appeared to be safe and induced detectable antibody-based immune responses in subjects.

In the Phase 2 clinical trial involving 600 participants in China, the candidate did not cause any serious side effect and the rate of fever was relatively low compared with other Covid-19 candidates, the paper showed ahead of peer review.

Sinovac has to test its vaccine abroad because China is no longer a satisfactory site for late-stage trials due to the low number of new infection cases.

Vaccine coming very soon...no joke !!

JAKARTA, Aug 11 — China's Sinovac Biotech Ltd launched today a late-stage human trial involving as many as 1,620 patients in Indonesia for a Covid-19 vaccine candidate that it is developing with Indonesian state-owned peer Bio Farma.

The candidate, known as CoronaVac and previously PiCoVacc, is among few potential vaccines that have entered late-stage trials for a large-scale study to gather proof of efficacy for regulatory approval.

CoronaVac is already undergoing a late-stage trial in Brazil slated for as many as 9,000 people.

Its Indonesia trial comes as South-east Asia's most populous country grapples with spiking infection numbers, with over 127,000 cases recorded as of today. The trial has so far recruited 1,215 people and will last six months.

A ceremony for the launch today in Bandung, West Java, was attended by Indonesia's President Joko Widodo.

“The threat of Covid-19 will not subside until a vaccine is given to all the people,” Widodo said.

Sinovac expects to also test the vaccine candidate in Bangladesh.

Separately, Sinovac late yesterday released details from a mid-stage, or Phase 2, study in which it said the vaccine candidate appeared to be safe and induced detectable antibody-based immune responses in subjects.

In the Phase 2 clinical trial involving 600 participants in China, the candidate did not cause any serious side effect and the rate of fever was relatively low compared with other Covid-19 candidates, the paper showed ahead of peer review.

Sinovac has to test its vaccine abroad because China is no longer a satisfactory site for late-stage trials due to the low number of new infection cases.

Kanasai recommendation

Bullsh#t article

The best blogger in i3investor...no over promote and very sincere analysing. Not like many other bloggers cum big sharks always recommended this stock that stock going to limit up and so on.